The Sprycel Market Size is valued at USD 5.47 Bn in 2022 and is predicted to reach USD 8.52 Bn by the year 2031 at a 5.2% CAGR during the forecast period for 2023-2031.
One of the effective cancer drugs is Sprycel. Adults with some significant forms of leukaemia (cancer of the white blood cells) are treated with it. Adult patients should use SPRYCEL® (dasatinib) for therapy. Newly discovered chronic myeloid leukaemia (CML) in the chronic phase that is Philadelphia chromosome-positive (Ph+) rapid, myeloid, lymphoid, or chronic blast phase Ph+ CML with intolerance or resistance to imatinib or earlier therapy.
SPRYCEL® is recommended for treating paediatric patients one year of age and older who have Ph+ ALL or acute lymphoblastic leukaemia with the Philadelphia chromosome. 'Chronic', 'accelerated', and 'blast' stages of CML. When alternative treatments, such as imatinib (another cancer medication), are ineffective or have unfavourable side effects, Sprycel is utilized.
Neutropenia, anaemia, and thrombocytopenia were the adverse events of Sprycel 100 mg once a day, which posed the most problems for the market. The hematologic adverse effects frequently start early in the course of therapy. Adverse non-hematological events typically manifest within the first two years of therapy.
According to the Phase I and II studies, headache, musculoskeletal pain, haemorrhage, infections, exhaustion, diarrhoea, pleural effusions, and nausea were the most frequent Non-hematological toxicities linked to the usage of Sprycel 100 mg once a day. Leukaemia and other blood-related diseases are becoming more common, awareness of treatment alternatives is developing, and major firms are investing more money in R&D efforts.
The sprycel market is segmented on the basis of demographic, psychographic, behavioural and medical. Based on demographics, the market is segmented as age, gender, and income. By psychographics, the market is segmented into lifestyle and attitudes. On the basis of behavioural, the market is segmented into usage rate, compliance, and treatment. As per the medical, the market is segmented into indication and disease stage.
The lifestyle category is expected to hold a major share in the global sprycel market in 2022. This is attributed to changes in the lifestyle of the population in developing countries. Moreover, the high income of most of the population anticipated the use of branded drugs for severe diseases such as cancer for better treatment.
The disease stage segment is projected to grow at a rapid rate in the global Sprycel market owing to the increasing use of the Sprycel in Philadelphia chromosome–positive (Ph+) chronic myeloid leukaemia (CML) in chronic phase (CP) treatment. Sprycel is used for adults with Ph+ CML who no longer respond well to conventional treatments, such as imatinib. Adults with Ph+ acute lymphoblastic leukaemia (Ph+ ALL) who no longer respond well to other treatments are treated by Sprycel, which is anticipated to push the market growth within the forecast period.
The North American sprycel market is expected to record the highest market revenue share in the near future. The use of Sprycel has expanded significantly as a result of an increase in research on hereditary uncommon disorders, chronic myelogenous leukaemia (CML), acute lymphoblastic leukaemia (ALL), and other types of leukaemia, the presence of key players in the area, and government funding.
| Report Attribute | Specifications |
| Market Size Value In 2022 | USD 5.47 Bn |
| Revenue Forecast In 2031 | USD 8.52 Bn |
| Growth Rate CAGR | CAGR of 5.2% from 2023 to 2031 |
| Quantitative Units | Representation of revenue in US$ Bn and CAGR from 2023 to 2031 |
| Historic Year | 2019 to 2022 |
| Forecast Year | 2023-2031 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Demographic, Psychographc, Behavioral, Medical |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South Korea; South East Asia |
| Competitive Landscape | Bristol-Myers Squibb (BMS), Novartis, Teva Pharmaceutical Industries, Mylan, Accord Healthcare, Sun Pharma, Dr. Reddy's Laboratories, Aurobindo Pharma |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Sprycel Market By Demographic-
Sprycel Market By Psychographic -
Sprycel Market By Behavioral -
Sprycel Market By Medical –
Sprycel Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Sprycel Market Snapshot
Chapter 4. Global Sprycel Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Demographic Estimates & Trend Analysis
5.1. By Demographic, & Market Share, 2020 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Demographic:
5.2.1. Age
5.2.2. Gender
5.2.3. Income
Chapter 6. Market Segmentation 2: By Psychographic Estimates & Trend Analysis
6.1. By Psychographic & Market Share, 2020 & 2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Psychographic:
6.2.1. Lifestyle
6.2.2. Attitudes
Chapter 7. Market Segmentation 3: By Behavioral Estimates & Trend Analysis
7.1. By Behavioral & Market Share, 2020 & 2031
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Behavioral:
7.2.1. Usage Rate
7.2.2. Compliance
7.2.3. Treatment History
Chapter 8. Market Segmentation 4: By Medical Estimates & Trend Analysis
8.1. By Medical & Market Share, 2020 & 2031
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Medical:
8.2.1. Indication
8.2.2. Disease Stage
Chapter 9. Sprycel Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. North America Sprycel Market revenue (US$ Million) estimates and forecasts By Demographic, 2019-2031
9.1.2. North America Sprycel Market revenue (US$ Million) estimates and forecasts By Psychographic, 2019-2031
9.1.3. North America Sprycel Market revenue (US$ Million) estimates and forecasts By Behavioral, 2019-2031
9.1.4. North America Sprycel Market revenue (US$ Million) estimates and forecasts By Medical, 2019-2031
9.1.5. North America Sprycel Market revenue (US$ Million) estimates and forecasts by country, 2019-2031
9.2. Europe
9.2.1. Europe Sprycel Market revenue (US$ Million) By Demographic, 2019-2031
9.2.2. Europe Sprycel Market revenue (US$ Million) By Psychographic, 2019-2031
9.2.3. Europe Sprycel Market revenue (US$ Million) By Behavioral, 2019-2031
9.2.4. Europe Sprycel Market revenue (US$ Million) By Medical, 2019-2031
9.2.5. Europe Sprycel Market revenue (US$ Million) by country, 2019-2031
9.3. Asia Pacific
9.3.1. Asia Pacific Sprycel Market revenue (US$ Million) By Demographic, 2019-2031
9.3.2. Asia Pacific Sprycel Market revenue (US$ Million) By Psychographic, 2019-2031
9.3.3. Asia Pacific Sprycel Market revenue (US$ Million) By Behavioral, 2019-2031
9.3.4. Asia Pacific Sprycel Market revenue (US$ Million) By Medical, 2019-2031
9.3.5. Asia Pacific Sprycel Market revenue (US$ Million) by country, 2019-2031
9.4. Latin America
9.4.1. Latin America Sprycel Market revenue (US$ Million) By Demographic, (US$ Million) 2019-2031
9.4.2. Latin America Sprycel Market revenue (US$ Million) By Psychographic, (US$ Million) 2019-2031
9.4.3. Latin America Sprycel Market revenue (US$ Million) By Behavioral, (US$ Million) 2019-2031
9.4.4. Latin America Sprycel Market revenue (US$ Million) By Medical, (US$ Million) 2019-2031
9.4.5. Latin America Sprycel Market revenue (US$ Million) by country, 2019-2031
9.5. Middle East & Africa
9.5.1. Middle East & Africa Sprycel Market revenue (US$ Million) By Demographic, (US$ Million) 2019-2031
9.5.2. Middle East & Africa Sprycel Market revenue (US$ Million) By Psychographic, (US$ Million) 2019-2031
9.5.3. Middle East & Africa Sprycel Market revenue (US$ Million) By Behavioral, (US$ Million) 2019-2031
9.5.4. Middle East & Africa Sprycel Market revenue (US$ Million) By Medical, (US$ Million) 2019-2031
9.5.5. Middle East & Africa Sprycel Market revenue (US$ Million) by country, 2019-2031
Chapter 10. Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profile
10.2.1. Bristol-Myers Squibb (BMS)
10.2.2. Novartis
10.2.3. Teva Pharmaceutical Industries
10.2.4. Mylan
10.2.5. Accord Healthcare
10.2.6. Sun Pharma
10.2.7. Dr. Reddy's Laboratories
10.2.8. Aurobindo Pharma